Roivant bags Chi­na rights to Nabri­va's an­tibi­ot­ic; Sin­ga­pore’s Aslan Phar­ma lines up an $86M IPO to fund piv­otal can­cer drug stud­ies

→ Roivant Sci­ences is dou­bling down on in­fec­tious dis­eases and the Chi­na mar­ket with a li­cens­ing agree­ment with Nabri­va Ther­a­peu­tics $NBRV, which is ex­pect­ing da­ta from a sec­ond Phase III for its lead an­tibi­ot­ic lefa­mulin this spring. For $5 mil­lion up­front, an undis­closed Roivant sub­sidiary gets an ex­clu­sive li­cense to de­vel­op and com­mer­cial­ize the com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia treat­ment in main­land Chi­na, Hong Kong, Macau and Tai­wan. Nabri­va is al­so in for up to $90 mil­lion in mile­stones, as well as dou­ble-dig­it roy­al­ties on sales. “This part­ner­ship demon­strates our com­mit­ment to build out a ro­bust pipeline of prod­ucts in Chi­na in ad­di­tion to de­r­azan­ti­nib,” said Roivant founder and CEO Vivek Ra­maswamy. “It is al­so in­dica­tive of our de­sire to de­vel­op treat­ments for in­fec­tious dis­eases be­yond he­pati­tis B virus.” Lefa­mulin had aced its first piv­otal PhI­II tri­al, and the Dublin-based com­pa­ny is ex­pect­ed to file for reg­u­la­to­ry ap­proval in the US af­ter the sec­ond read­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER